Arca
Skip to content
Tools
Tools

F7: Coagulation factor VII

Initiates the extrinsic pathway of blood coagulation.

  • Drugs that act on it: 6
  • Approved: 3
  • In phases 1 to 3: 3
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on F7, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Protein or peptide 3
  • Other 2

Approved3

  • Coagulation factor vii human
  • Eptacog alfa (activated)
  • Eptacog beta (activated)

Phase 31

Phase 22

  • Eptacog alfa pegol (activated)
  • PCI-27483

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Shanghai RAAS Blood Products Co., Ltd.117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 6 act as: Coagulation factor VII exogenous protein; the rest name their own mechanism.
    Coagulation factor vii humanApprovedShanghai RAAS Blood Products Co., Ltd.Protein or peptideExogenous protein4
    Eptacog alfa (activated)ApprovedRocheProtein or peptideExogenous protein4
    Eptacog beta (activated)Approved—OtherExogenous protein0
    Prothrombin complex concentratePhase 3PfizerProtein or peptideExogenous protein32
    Eptacog alfa pegol (activated)Phase 2Novo NordiskOtherExogenous protein0
    PCI-27483Phase 2AbbVieSmall moleculeInhibitorCoagulation factor VII inhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
    A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsProthrombin complex concentratePhase 3RecruitingPfizerNov 9, 2026
    A Study to Describe Patient REal-world FitusiRan ExpeRienceProthrombin complex concentrate—Not yet recruitingSanofiOct 26, 2026
    Prothrombin Complex Concentrate (PCC)Prothrombin complex concentratePhase 4Not yet recruitingUniversity of MiamiOct 19, 2026
    Very Low-volume Plasma Exchange in ACLFProthrombin complex concentrateNot applicableNot yet recruitingThird Affiliated Hospital, Sun Yat-Sen UniversityOct 5, 2026
    A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII DeficiencyCoagulation factor vii humanPhase 2Not yet recruitingShanghai RAAS Blood Products Co., Ltd.Jul 17, 2026
    PCC Treatment for Hemophilia Patients With Inhibitor(2022PCC-A)Prothrombin complex concentratePhase 4RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaFeb 12, 2026
    A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII DeficiencyCoagulation factor vii humanPhase 2RecruitingHemab ApSJan 16, 2026
    Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)Prothrombin complex concentratePhase 3RecruitingCSL BehringJul 30, 2025
    An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentEptacog alfa (activated), Prothrombin complex concentrate—Active, not recruitingHoffmann-La RocheMar 19, 2025
    Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral HemorrhageProthrombin complex concentrate—Not yet recruitingQianfoshan HospitalOct 10, 2024
    SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsCoagulation factor vii human, Eptacog alfa (activated)Phase 4RecruitingAmerican Thrombosis and Hemostasis NetworkNov 30, 2020
    Treatment of Hemophilia A Patients With FVIII InhibitorsCoagulation factor vii human, Eptacog alfa (activated)—RecruitingEmory UniversityJul 17, 2019
    Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke TrialEptacog alfa (activated)Phase 3Active, not recruitingJoseph Broderick, MDApr 12, 2018

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Factor VII deficiency0.85
    • Congenital factor VII deficiency0.78
    • Blood coagulation disease0.55
    • Abnormality of coagulation0.44
    • Coagulation protein disease0.41
    • Abnormal bleeding0.40
    • Glanzmann thrombasthenia 10.38
    • Intracerebral hemorrhage0.37

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3991, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08709, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.